Company patents
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. appears to be significantly scaling back its patenting efforts across its core pharma_biotech categories, with "Pharmaceutical Preparations" (71.4% of portfolio) showing a -71.4% decline so far in 2026, and "Peptides & Proteins" (47.6% of portfolio) also down -50.0% in 2026, suggesting a broad shift in R&D focus or a strategic divestment from active patenting in these areas. Surprisingly, despite its strong pharma_biotech focus, the company also previously held patents in "Packaging Machines," which saw a 100.0% YoY growth in 2024 before a complete decline in 2026, indicating a brief, perhaps experimental, foray into manufacturing-related IP that has since been abandoned.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
42 US filings (since 2023) · 9 categories · 12 themes
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Methods and apparatuses for creating unique package structures, such as recesses in specific materials, blister packages, or single-dose units, and for controlled dispensing of products from storage into these containers.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.
Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.
Design and application of devices that are inserted into the body or implanted to treat diseases, modulate physiological functions, or repair anatomical structures.
Patents
Showing 1-6 of 6
Cellular Immunotherapy